2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons

After a downbeat start to 2025, biopharma struck some high notes in the second half and ended the year with strong Q4 momentum in dealmaking, fundraising and M&A. The numbers, once again tracked for us ...